EXAS Exact Sciences Corp

Price (delayed)

$117.95

Market cap

$20.23B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.07

Enterprise value

$21.5B

Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Exact Sciences Corp. launched Cologuard in 2014, the first ...

Highlights
The company's equity has surged by 63% QoQ and by 44% YoY
EXAS's revenue is up by 46% year-on-year and by 3.6% since the previous quarter
The company's quick ratio has shrunk by 54% YoY and by 20% QoQ
The company's debt rose by 42% YoY

Key stats

What are the main financial stats of EXAS
Market
Shares outstanding
171.55M
Market cap
$20.23B
Enterprise value
$21.5B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.47
Price to sales (P/S)
12.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.91
Earnings
Revenue
$1.55B
EBIT
-$948.2M
EBITDA
-$769.21M
Free cash flow
$44.5M
Per share
EPS
-$5.07
Free cash flow per share
$0.26
Book value per share
$21.58
Revenue per share
$9.12
TBVPS
$14.62
Balance sheet
Total assets
$6.73B
Total liabilities
$3.09B
Debt
$2.37B
Equity
$3.65B
Working capital
$1.15B
Liquidity
Debt to equity
0.65
Current ratio
2.82
Quick ratio
2.6
Net debt/EBITDA
-1.65
Margins
EBITDA margin
-49.8%
Gross margin
75.2%
Net margin
-50.1%
Operating margin
-63.8%
Efficiency
Return on assets
-15.1%
Return on equity
-28.8%
Return on invested capital
-31.7%
Return on capital employed
-15.5%
Return on sales
-61.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXAS stock price

How has the Exact Sciences stock price performed over time
Intraday
-0.07%
1 week
3.46%
1 month
-9.94%
1 year
20.68%
YTD
-10.97%
QTD
-5.12%

Financial performance

How have Exact Sciences's revenue and profit performed over time
Revenue
$1.55B
Gross profit
$1.16B
Operating income
-$986.19M
Net income
-$774M
Gross margin
75.2%
Net margin
-50.1%
The operating margin has dropped by 173% year-on-year and by 24% since the previous quarter
EXAS's revenue is up by 46% year-on-year and by 3.6% since the previous quarter
EXAS's gross profit is up by 44% year-on-year and by 2.3% since the previous quarter
The operating income has declined by 28% since the previous quarter

Growth

What is Exact Sciences's growth rate over time

Valuation

What is Exact Sciences stock price valuation
P/E
N/A
P/B
5.47
P/S
12.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.91
Exact Sciences's EPS has increased by 10% from the previous quarter
The company's equity has surged by 63% QoQ and by 44% YoY
The stock's price to book (P/B) is 41% less than its 5-year quarterly average of 9.2 and 18% less than its last 4 quarters average of 6.7
EXAS's revenue is up by 46% year-on-year and by 3.6% since the previous quarter
EXAS's price to sales (P/S) is 29% less than its 5-year quarterly average of 18.1

Efficiency

How efficient is Exact Sciences business performance
Exact Sciences's ROS has plunged by 185% YoY and by 20% from the previous quarter
The company's return on invested capital has shrunk by 156% YoY and by 21% QoQ
EXAS's return on assets is up by 19% since the previous quarter
The ROE has grown by 18% from the previous quarter

Dividends

What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXAS.

Financial health

How did Exact Sciences financials performed over time
The total assets is 118% more than the total liabilities
The total liabilities has surged by 60% year-on-year and by 15% since the previous quarter
The company's quick ratio has shrunk by 54% YoY and by 20% QoQ
The company's debt is 35% lower than its equity
The company's equity has surged by 63% QoQ and by 44% YoY
The company's debt rose by 42% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.